KRYS vs VRTX · P/E 46, rev $235.6M vs P/E 30, rev $3.33B
Krystal Biotech Inc (KRYS) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Krystal Biotech Inc (KRYS) is a biotechnology company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported KRYS revenue for 2026-06-30 was $235.6M. Net income was $110.7M. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
KRYS currently screens at market cap $10.17B and trailing P/E 46.1. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the KRYS and VRTX stock pages for the full models.
Not investment advice.